Orchid Pharma has received final USFDA approval for Aripiprazole Orally-Disintegrating tablets, used in treatment of schizophrenia and bipolar disorder. The drug will be made available in Orally-Disintegrating tablets USP of 10 mg and 15 mg. The tablets are atypical antipsychotic, indicated in the treatment of symptoms related to psychotic conditions such as schizophrenia and bipolar disorder (manic depression).
Company Profile : Orchid Chemicals And Pharmaceuticals Ltd
Leave a Reply